Spike vs. nucleocapsid serum antigens for COVID-19 diagnosis and severity assessment

Clin Chem Lab Med. 2022 Jan 11;60(5):e97-e100. doi: 10.1515/cclm-2021-1244. Print 2022 Apr 26.

Authors

Julien Favresse^{1

2}, Jean-Louis Bayart³, Clara David⁴, Marie Didembourg², Constant Gillot², Jean-Michel Dogné², Jonathan Douxfils^{2

4}

Affiliations

¹ Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium.
² Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium.
³ Department of Laboratory Medicine, Clinique St-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium.
⁴ Qualiblood sa, Namur, Belgium.

PMID: 35007411
DOI: 10.1515/cclm-2021-1244

No abstract available

Keywords: COVID-19; RT-PCR; SARS-CoV-2; antigenic assay; disease severity.

Publication types

Letter

MeSH terms

Antibodies, Viral
COVID-19 Testing
COVID-19* / diagnosis
Humans
Nucleocapsid
Sensitivity and Specificity
Spike Glycoprotein, Coronavirus

Substances

Antibodies, Viral
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2